This topic contains a solution. Click here to go to the answer

Author Question: The greater the therapeutic window a. The lower the LD50/ED50 ratio. b. The more likely a drug ... (Read 39 times)

frankwu

  • Hero Member
  • *****
  • Posts: 549
The greater the therapeutic window
 
  a. The lower the LD50/ED50 ratio.
  b. The more likely a drug is to cause death at therapeutic drug
  concentrations.
  c. The less likely a drug is to cause death at therapeutic concentrations.
  d. The higher the efficacy.

Question 2

Steady state is reached in
 
  a. Three half-lives.
  b. Five half-lives.
  c. Seven half-lives.
  d. Nine half-lives.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Ahnyah

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

c

Answer to Question 2

b




frankwu

  • Member
  • Posts: 549
Reply 2 on: Jun 22, 2018
YES! Correct, THANKS for helping me on my review


mcarey591

  • Member
  • Posts: 365
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Colchicine is a highly poisonous alkaloid originally extracted from a type of saffron plant that is used mainly to treat gout.

Did you know?

The Centers for Disease Control and Prevention has released reports detailing the deaths of infants (younger than 1 year of age) who died after being given cold and cough medications. This underscores the importance of educating parents that children younger than 2 years of age should never be given over-the-counter cold and cough medications without consulting their physicians.

Did you know?

Hip fractures are the most serious consequences of osteoporosis. The incidence of hip fractures increases with each decade among patients in their 60s to patients in their 90s for both women and men of all populations. Men and women older than 80 years of age show the highest incidence of hip fractures.

Did you know?

Certain topical medications such as clotrimazole and betamethasone are not approved for use in children younger than 12 years of age. They must be used very cautiously, as directed by a doctor, to treat any child. Children have a much greater response to topical steroid medications.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library